Matinas BioPharma Announces Director Changes and Executive Compensation
Ticker: MTNB · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Matinas BioPharma board shake-up: new directors in, one out. Executive pay details also filed.
AI Summary
On June 23, 2025, Matinas BioPharma Holdings, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Terry L. Horgan and the election of new directors, including Dr. Steven M. R. Smith and Mr. Paul E. Clancy. Additionally, the filing covers compensatory arrangements for certain officers and the submission of matters to a vote of security holders.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and executive compensation filings can sometimes precede or reflect significant strategic shifts or financial performance issues.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- Dr. Terry L. Horgan (person) — Departing Director
- Dr. Steven M. R. Smith (person) — Newly Elected Director
- Mr. Paul E. Clancy (person) — Newly Elected Director
FAQ
Who has departed from the Board of Directors of Matinas BioPharma Holdings, Inc.?
Dr. Terry L. Horgan has departed from the Board of Directors.
Who were elected as new directors to the Board of Matinas BioPharma Holdings, Inc.?
Dr. Steven M. R. Smith and Mr. Paul E. Clancy were elected as new directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated June 23, 2025.
What are the main items covered in this Form 8-K filing?
The filing covers the departure of directors, election of directors, compensatory arrangements of certain officers, and submission of matters to a vote of security holders.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 by Dr. Terry L. Horgan regarding Matinas BioPharma Holdings, Inc. (MTNB).